Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 8/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.39 |
| ▸ | PAK4 | O96013 | 2/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786532 | 0.83 | IGF1R (0.44) | HTR2CHTR2AIGF1RPAK1PAK4 | |
| SCHEMBL801995 | 0.82 | PAK1 (0.52) | IGF1RPAK1PAK4INSR | |
| SCHEMBL786662 | 0.82 | MAPT (0.40) | HTR2CHTR2AIGF1RPAK1PAK4 | |
| SCHEMBL802283 | 0.81 | HTR2C (0.40) | HTR2CHTR2AIGF1RPAK1PAK4 | |
| SCHEMBL786214 | 0.80 | ACHE (0.54) | PAK1PAK4ROCK2ACHEROCK1 | |
| SCHEMBL786361 | 0.77 | PAK4 (0.65) | HTR2CHTR2APAK1PAK4LMNA | |
| SCHEMBL786291 | 0.70 | OGA (0.51) | HTR2CLMNAGAAALOX15SMN1; SMN2 | |
| SCHEMBL786824 | 0.67 | PAK4 (0.53) | HTR2APAK1PAK4LMNAGAA | |
| SCHEMBL802259 | 0.65 | CCR4 (0.59) | HTR2APAK1PAK4LMNAGAA | |
| SCHEMBL801630 | 0.65 | IGF1R (0.46) | IGF1RPAK1PAK4INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1317448-B2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | HTR2C 2651/4885HTR2A 3676/4885IGF1R 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.